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OBJECTIVE—The orexigenic gut hormone ghrelin and its re-
ceptor are present in pancreatic islets. Although ghrelin reduces
insulin secretion in rodents, its effect on insulin secretion in
humans has not been established. The goal of this study was to
test the hypothesis that circulating ghrelin suppresses glucose-
stimulated insulin secretion in healthy subjects.
RESEARCH DESIGN AND METHODS—Ghrelin (0.3, 0.9 and
1.5 nmol/kg/h) or saline was infused for more than 65 min in 12
healthy patients (8 male/4 female) on 4 separate occasions in a
counterbalanced fashion. An intravenous glucose tolerance test
was performed during steady state plasma ghrelin levels. The
acute insulin response to intravenous glucose (AIRg) was calcu-
lated from plasma insulin concentrations between 2 and 10 min
after the glucose bolus. Intravenous glucose tolerance was
measured as the glucose disappearance constant (Kg) from 10 to
30 min.
RESULTS—The three ghrelin infusions raised plasma total
ghrelin concentrations to 4-, 15-, and 23-fold above the fasting
level, respectively. Ghrelin infusion did not alter fasting plasma
insulin or glucose, but compared with saline, the 0.3, 0.9, and 1.5
nmol/kg/h doses decreased AIRg (2,152  448 vs. 1,478  2,889,
1,419  275, and 1,120  174 pmol/l) and Kg (0.3 and 1.5
nmol/kg/h doses only) signiﬁcantly (P  0.05 for all). Ghrelin
infusion raised plasma growth hormone and serum cortisol
concentrations signiﬁcantly (P  0.001 for both), but had no
effect on glucagon, epinephrine, or norepinephrine levels (P 
0.44, 0.74, and 0.48, respectively).
CONCLUSIONS—This is a robust proof-of-concept study show-
ing that exogenous ghrelin reduces glucose-stimulated insulin
secretion and glucose disappearance in healthy humans. Our
ﬁndings raise the possibility that endogenous ghrelin has a role in
physiologic insulin secretion, and that ghrelin antagonists could
improve -cell function. Diabetes 59:2145–2151, 2010
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hrelin has gained considerable attention over
the last decade for its unique role in regulating
mealtime hunger and lipid metabolism, as well
as short- and long-term energy homeostasis
(1–3). It is the only known circulating factor that promotes
food intake and increases fat mass. Ghrelin is secreted
mainly from the stomach and proximal small bowel, and
stimulates growth hormone (GH) secretion (4–6), in ad-
dition to its effect on energy balance. In healthy subjects,
plasma ghrelin levels rise progressively before meals and
fall to a nadir within 1 hour after eating, with changes in
plasma levels during meals varying two- to threefold (7–8).
Under pathologic conditions associated with severe mal-
nutrition and weight loss, such as anorexia nervosa (9),
cancer, or cardiac cachexia (10–11), plasma total ghrelin
levels are increased up to threefold compared with healthy
individuals. Besides its well known effects on feeding
behavior, fat mass, and GH secretion, ghrelin has recently
been implicated in the regulation of glucose homeostasis
(12–13).
The GH secretagogue receptor (GHSR)-1a, also known
as the ghrelin receptor, is widely distributed and has been
localized to the hypothalamus, pituitary, liver, adipocyte,
and pancreas (14–15). Both ghrelin and GHSR are ex-
pressed in human and rat pancreatic islets on both -
(16–17) and -cells (18–19), and ghrelin is produced in a
novel endocrine islet cell type that shares lineage with
glucagon-secreting cells (20–21). Pancreatic ghrelin cells
exist as the predominant cell type in fetal human islets,
and expression in the pancreas during development signif-
icantly precedes its occurrence in the stomach (20). In
animal mutant models, an early block in the differentiation
of insulin-producing  cells leads to an enormous increase
in ghrelin-producing ε cells, suggesting a developmental
link between ghrelin and insulin (22). In vitro, ghrelin
inhibits glucose-stimulated insulin secretion in a dose-
dependent manner from cultured pancreata (23), isolated
pancreatic islets (19,24), and immortalized -cell lines
(19,21), suggesting that it acts directly on  cells to achieve
this effect. In experimental animals, both ghrelin released
from pancreatic islets and exogenous ghrelin inhibit glu-
cose-stimulated insulin secretion (16,24–26). Targeted
gene deletion of ghrelin improves glucose tolerance and
augments insulin secretion in ob/ob mice, suggesting a
possible physiologic role which could be mediated by
effects on islet function (27). Consistent with these ﬁnd-
ings, ghrelin gene deletion was shown to prevent glucose
intolerance induced by a high-fat diet, an environmentally-
induced model of hyperglycemia (26). Together, these
ﬁndings indicate the potential of ghrelin blockade to
prevent both genetically (ob gene)- and environmentally
(high-fat diet)-induced glucose intolerance.
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controversial. Intravenous injection of ghrelin decreases
plasma insulin and increases blood glucose in some stud-
ies, suggesting inhibition of insulin secretion (12,28). How-
ever, this ﬁnding has not been universally observed (29),
and it is unclear whether such effects occur at physiologic
or only pharmacologic doses of ghrelin. Prior studies
performed in humans primarily assessed the impact of
ghrelin on -cell function in the fasting state, and there is
little information on the effect of the peptide on stimulated
insulin release. Therefore, the role of ghrelin in the regu-
lation of glucose homeostasis in humans remains poorly
understood.
In this study, we determined the effect of ghrelin on
glucose-stimulated insulin secretion and glucose toler-
ance. We infused acyl-ghrelin, the bioactive endogenous
ligand of the GHSR-1a, at variable doses with the aim of
raising plasma total ghrelin level to physiologic (less than
twofold), supraphysiologic (two- to threefold) and phar-
macologic (more than threefold) levels. An intravenous
glucose tolerance test (IVGTT) was performed at steady
state plasma ghrelin levels to determine the effect on
glucose-stimulated insulin secretion and glucose tolerance
in healthy, nonobese subjects.
RESEARCH DESIGN AND METHODS
Subjects. Healthy volunteers between the ages of 18 and 55 years with a BMI
between 18 and 29 kg/m
2 were recruited from the greater Cincinnati area.
Subjects with a history or clinical evidence of impaired fasting glucose or
diabetes, recent myocardial infarction, congestive heart failure, active liver or
kidney disease, growth hormone deﬁciency or excess, neuroendocrine tumor,
anemia, or who were on medications known to alter insulin sensitivity were
excluded.
All study procedures were conducted at the Cincinnati Veteran Affairs
Medical Center General Clinical Research Center. All study participants gave
informed consent for the study by signing a form approved by University of
Cincinnati Institutional Review Board.
Experimental protocol. Subjects arrived at the Clinical Research Center
between 0700 and 0730 after a 10–12 h fast for four separate experiments.
intravenous catheters were placed in the veins of both forearms for blood
sampling and infusion of test substances. The arm with the sampling catheter
was heated to 55°C to arterialize venous blood.
Synthetic human acylated ghrelin was obtained from Bachem AG (Ruben-
dorf, Switzerland). The authenticity of the peptide was veriﬁed by mass
spectrometry, the purity was 95%, and reconstituted material was sterile and
free of detectable pyrogens. On the morning of the 4 study days, either saline
(as a control) or synthetic ghrelin dissolved in sterile saline solution was
infused at doses of 0.3, 0.9, or 1.5 nmol/kg/h (equivalent to 1, 3, or 5 g/kg/h)
for a total of 65 min. The order of infusions was randomized, and study visits
separated by at least 5 days. The use of synthetic human ghrelin was approved
under the U.S. Food and Drug Administration Investigational New Drug
79,009.
After 55 min of ghrelin infusion,  6 plasma half-lives of acyl-ghrelin (28),
subjects received an intravenous bolus of glucose (11.4 g/m
2 body surface
area) over 60 s as the initiation of an IVGTT (time 0). Blood samples were
removed at 2, 3, 4, 5, 6, 8, and 10 min after intravenous glucose bolus for the
estimation of acute insulin response to glucose (AIRg) and acute C-peptide
response to glucose (ACRg). Another seven blood samples were taken at 12,
14, 16, 20, 22, 25, and 30 min for the calculation of glucose disappearance and
ghrelin pharmacokinetics. Blood was placed on ice and plasma separated by
centrifugation within 1 hour, with the plasma stored at 	80°C until used for
assay. Blood pressure and heart rate were monitored every 15 min during the
study procedure. A complete blood count, liver and kidney function tests, and
an electrocardiogram were obtained as part of the safety monitoring of ghrelin
use at the end of the last visit.
Assays. Blood glucose concentrations were determined by the glucose
oxidase method using a glucose analyzer (YSI 2,300 STAT Plus; Yellow Springs
Instruments, Yellow Springs, OH). Plasma immunoreactive insulin levels were
measured using a double-antibody radioimmunoassay (RIA) as described
previously (30). C-peptide levels were measured using a commercial RIA kit
(Millipore). Total immunoreactive ghrelin was measured by RIA (Millipore,
Billarica, MA). The lower and upper limits of detection were 27 and 1,765
pmol/l (93 and 6,000 pg/ml), respectively, and the intra-assay and interassay
coefﬁcients of variation (CV) were 6.4 and 16.3%, respectively. The ghrelin
antibody used in the assay was directed toward the C-terminus of the
molecule and binds both acyl- and desacyl-ghrelin, as well as truncated ghrelin
species. Serum concentrations of human GH (hGH) were measured using the
automated Immulite 2000 chemiluminescent assay system (Siemens, Bad
Nauheim, Germany). This sandwich immunoassay uses a monoclonal mouse-
anti-hGH capture- and a polyclonal rabbit-anti-hGH detection antibody. The
intra-assay CV was 3%, and interassay variability ranged from 7%. Samples for
glucagon were collected with benzamidine and heparin and were measured by
RIA (Millipore, Billarica, MA). Cortisol levels were measured using the
Corti-Cote RIA kit (MP Biomedicals, Orangeburg, NY). Plasma epinephrine
and norepinephrine were measured using the CatCombi ELISA kit (IBL
International; Hamburg, Germany). All samples were run in duplicate, and all
specimens from a given participant were processed in the same assay.
Calculations. AIRg and ACRg were calculated as the average plasma insulin
and C-peptide increment above baseline from 2–10 min after intravenous
glucose administration, respectively. The glucose disappearance constant (31)
was computed for each IVGTT as the slope of the natural logarithm of glucose
from 10 to 30 min. The rate of ghrelin disappearance was calculated as the
slope of the natural logarithm of ghrelin after cessation of the ghrelin infusion
at 65 min (10 min after the glucose bolus was given).
Statistical analysis. The data were analyzed using ANOVA with 4 treatment
levels (control, and ghrelin infusion rates of 0.3, 0.9, and 1.5 nmol/kg/h) and
time of sampling being the repeated measure. Dependent variables included
insulin, glucose, GH, cortisol, and glucagon concentrations. AIRg and ACRg
for the 4 treatment levels were compared using a single-factor ANOVA. Post
hoc analysis to compare control with each of the ghrelin infusion levels was
performed using a Dunnett test. Data were analyzed using GraphPad Prism
version 5.0 (GraphPad Software). All results are expressed as mean  SEM
unless otherwise noted.
RESULTS
Subject characteristics. Twelve healthy subjects (8 male
and 4 female) age 26.0  3.8 years with a BMI of 24.1  1.4
kg/m
2 were enrolled in the study. No subject had a fasting
blood glucose of 5.5 mmol/l. Mean fasting blood glucose
for the group was 4.9  0.2 mmol/l, and mean fasting
plasma insulin was 37.8  6.2 pmol/l.
Ghrelin pharmacokinetics. Steady-state levels were
reached after 45 min for all 3 doses of acyl-ghrelin
infusion. The average total ghrelin concentration during
the time period between 45 and 54 min (10, 5, and 1 min
before to intravenous glucose administration) for saline
and the 3 acyl-ghrelin infusions were 304  18, 1,429  49,
4,629  194, and 7,045  295 pmol/l. The 0.3, 0.9 and 1.5
nmol/kg/h infusions raised the total ghrelin immunoreac-
tivity 4.5 -, 15.4 -, and 22.6 - fold above an average basal
level of 308  30 pmol/l for the three infusions (Fig. 1;
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FIG. 1. Plasma total ghrelin levels during continuous intravenous infu-
sions (minus 15 to 65 min) of saline, 0.3, 0.9, or 1.5 nmol/kg/h of acyl
ghrelin in healthy men and women. A bolus intravenous dose of glucose
(11.4 g/m
2 body surface area) was infused more than 1 min after plasma
ghrelin had reached a steady state (55 min). The acyl ghrelin infusions
resulted in a dose-dependent increase in plasma ghrelin.
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-0504/DC1). The intrasubject CV percentage for the saline,
0.3, 0.9, and 1.5 nmol/kg/h ghrelin infusions were 13.8, 7.7,
6.8, and 7.0%, respectively. The intersubject CV percentage
for the steady-state total ghrelin measurement with dif-
ferent ghrelin infusion rates were 23.7, 20.1, 14.6, and
24.1%, respectively. After cessation of the ghrelin infusion
at 65 min, total ghrelin levels declined after a ﬁrst-order
(exponential) decrease with an overall elimination rate
constant (Kel) of 0.023 min
	1, corresponding to an elimi-
nation half-life of 30 min.
Effects of exogenous ghrelin on plasma insulin and
glucose. The average fasting plasma glucose and insulin
values at baseline and at times when ghrelin concentration
reached a steady state (45 to 54 min) are shown in Table 1.
Infusion of exogenous ghrelin did not alter fasting plasma
concentrations of insulin and glucose from baseline (P 
0.05 for all comparisons).
Compared with saline, the doses of 0.3, 0.9, and 1.5
nmol/kg/h ghrelin each resulted in a signiﬁcant reduction
of AIRg (2,152  448 to 1,478  288, 1,419  2,751 and
1,210  188 pmol/l, P  0.05,  0.05, and  0.01,
respectively) during an IVGTT (Fig. 2A and B). The mag-
nitude of suppression in AIRg increased with higher doses
of ghrelin administration, suggesting a dose-dependent
relationship between circulating ghrelin concentration and
insulin secretion. Similar to AIRg, a signiﬁcant suppression
of C-peptide release in response to intravenous glucose
was also seen with all three doses of ghrelin infusions
(5.8  0.9 to 4.1  0.4, 4.2  0.5, and 3.6  0.6 nmol/l, P 
0.05,  0.05, and  0.01, respectively) (Fig. 2C). In
addition, ghrelin infusion at the 0.3 and 1.5 nmol/kg/h
doses also signiﬁcantly decreased the rate of glucose
disappearance (P  0.05 for both comparisons; Fig. 3).
Effects of exogenous ghrelin on counterregulatory
hormones. The three doses of ghrelin raised peak plasma
GH levels by 12-, 114-, and 75-fold above baseline, respec-
tively (Fig. 4). The 0.9 and 1.5 nmol/kg/h rates of ghrelin
infusion also raised plasma cortisol levels signiﬁcantly as
compared with baseline at 30, 54, and 65 min (P  0.01)
(Fig. 5). Ghrelin infusion, regardless of dose, had no effect
on glucagon secretion (P  0.44) (supplementary Fig. 1).
Plasma epinephrine and norepinephrine levels did not
differ between baseline and 54 min when ghrelin in the
circulation reached a steady state, regardless of the type of
infusion the subjects received (supplementary Fig. 2).
Side effects. Ghrelin infusion was generally well toler-
ated. The most common complaints during infusion of
ghrelin were hunger and “warm sensation.” These symp-
toms were transient and resolved spontaneous after ces-
TABLE 1
Basal plasma glucose and insulin levels during continuous intravenous infusions of saline, 0.3, 0.9, or 1.5 nmol/kg/h acyl ghrelin (0–54
min) before an IVGTT
Infusion rate
Plasma glucose (mg/dl) Plasma insulin (pM)
Baseline
Ghrelin steady state
(t  45–54 min) Baseline
Ghrelin steady state
(t  45–54 min)
Saline 83.8  4.6 86.9  1.0 34.1  4.8 36.5  5.8
Ghrelin (0.3 nmol/kg/h) 86.5  2.4 96.7  6.7 36.3  4.8 30.4  5.0
Ghrelin (0.9 nmol/kg/h) 91.4  2.1 93.5  2.7 42.0  6.6 36.1  6.9
Ghrelin (1.5 nmol/kg/h) 87.6  1.6 91.5  2.4 39.1  5.8 25.6  3.9
Data for baseline plasma glucose and insulin concentration were calculated as the average of the 	15- and 	1-min values. Data for plasma
glucose and insulin at steady-state ghrelin concentration were calculated as the average of 45, 50, and 54 min values.
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FIG. 2. A: Plasma insulin concentrations during an IVGTT after 55-min
infusions of acyl ghrelin at 0.3, 0.9, or 1.5 nmol/kg/h, or saline. B: The
acute insulin response to intravenous glucose (AIRg) determined
during infusions of acyl ghrelin at 0.3, 0.9, or 1.5 nmol/kg/h dose, or
saline. *P < 0.05, **P < 0.01. C: The acute C-peptide response to
intravenous glucose (ACRg) determined during infusions of acyl ghre-
lin at 0.3, 0.9, or 1.5 nmol/kg/h dose, or saline. *P < 0.05, **P < 0.01.
J. TONG AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, SEPTEMBER 2010 2147sation of the infusion. One subject, while receiving the 1.5
nmol/kg per hour ghrelin infusion, experienced a 23-
mmHg decrease in mean arterial blood pressure without a
signiﬁcant change in heart rate. The subject was asymp-
tomatic except for feeling “warm and hungry” during the
event. The blood pressure returned to baseline within
minutes after the ghrelin infusion was discontinued pre-
maturely. This blood pressure change was not observed in
any other subject or with any other dose.
DISCUSSION
Preclinical studies support a role for ghrelin to regulate
glucose metabolism as well as energy balance and GH
secretion. However, the effect of ghrelin on insulin secre-
tion and glucose tolerance in humans has not been clearly
established in the limited number of studies reported
previously. In the present study, we examined the effect of
a range of ghrelin doses on dynamic insulin secretion and
glucose metabolism and demonstrated that acyl-ghrelin
suppresses glucose-stimulated insulin secretion and wors-
ens intravenous glucose tolerance in healthy humans.
These effects appear to be present at concentrations of
ghrelin above the usual physiologic range, and in a pattern
consistent with dose-dependence. Our ﬁndings extend to
humans the effects previously best demonstrated in mice,
and suggest that ghrelin has a role in systemic glucose
homeostasis. Moreover, our results raise possibilities for
targeting the human ghrelin system as a means to improve
disorders of glucose metabolism.
Several studies have examined the effect of ghrelin on
insulin secretion in humans. In a study of healthy young
males by Broglio et al. (12), an intravenous bolus injection
of ghrelin (0.3 nmol/kg or 1.0 g/kg) signiﬁcantly increased
fasting plasma glucose levels followed by a reduction in
serum insulin levels beginning at 15 and 30 min after
ghrelin administration, respectively, suggesting inhibition
of insulin secretion. When the same dose of ghrelin was
given as a continuous intravenous infusion to subjects
who had undergone total gastrectomy, by necessity reduc-
ing the production of most endogenous ghrelin, C-peptide
levels were suppressed when compared with saline infu-
sion (32). In contrast, Lucidi et al. (29) infused acyl ghrelin
at a rate of 7.5 or 15 pmol/kg/min for 2 hours in 8 healthy
subjects and failed to observe a signiﬁcant change in
fasting plasma glucose and insulin levels. However, all
previous studies in humans used fasting insulin as the
marker of ghrelin effects on the -cell, with no examina-
tion of stimulated insulin secretion. In the present study,
we examined the effect of continuous infusions of low,
medium, and high doses of acyl ghrelin on AIRg, a well
established measure of insulin secretion that we think
provides a more sensitive measure of -cell function. The
measure of C-peptide levels during the IVGTT conﬁrms the
changes in AIRg, and supports an effect of ghrelin on
insulin secretion rather than insulin clearance. Moreover,
the continuous infusion of ghrelin during the IVGTT also
eliminated any potential bias in the -cell response intro-
duced by rapid changes in plasma ghrelin levels as occur
with a bolus injection of the peptide. Based on these
design advantages. we believe that ours is the most robust
proof-of-concept study yet of the effect of ghrelin on
insulin secretion in humans.
Similar to Lucidi et al. (29), we did not observe a
signiﬁcant change in fasting insulin or glucose levels with
any of the 3 doses of ghrelin. On the other hand, we did
ﬁnd a clear suppressive effect of ghrelin on the ﬁrst-phase
insulin response in an apparent dose-dependent fashion,
with the greatest effect seen with the highest dose ghrelin
(Fig. 2). In addition, the decrease in intravenous glucose
tolerance is consistent with a reduction of insulin secre-
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FIG. 5. Plasma cortisol concentrations during a 65-min infusion of
acyl ghrelin at 0.3, 0.9, or 1.5 nmol/kg/h, or saline. Glucose was
administered as an intravenous bolus after 55 min of the infusion. b
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FIG. 3. Glucose disappearance constant (Kg) determined during
infusions of acyl ghrelin at 0.3, 0.9, or 1.5 nmol/kg/h, or saline. *P <
0.05.
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FIG. 4. Plasma growth hormone concentrations during a 65-min infu-
sion of acyl ghrelin at 0.3, 0.9, or 1.5 nmol/kg/h, or saline. Glucose was
administered as an intravenous bolus after 55 min of the infusion. a, b,
and c are saline vs. 0.3, 0.9, or 1.5 nmol/kg/h of ghrelin, respectively;
*P < 0.05, ***P < 0.001.
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studies that have provided evidence that ghrelin has an
inhibitory effect on stimulated insulin secretion from pan-
creatic -cells (16,19,21,24–26) and in vivo studies that
have shown a deteriorating effect on glucose tolerance
(25,27). The mechanisms by which ghrelin could inhibit
insulin secretion are unknown. Ghrelin may exert a direct
effect on the -cell or act indirectly by stimulating the
secretion of counter-regulatory hormones that affect insu-
lin secretion, or activating neural pathways that regulate
islet function (33–38). The signaling mechanisms for insu-
linostatic ghrelin action in islet -cells have been explored.
Both endogenous and exogenous ghrelin has been shown
to attenuate glucose-induced insulin release via Gi2-
mediated activation of Kv channels, and suppression of
action potential ﬁring and [Ca
2
]i increases in -cells (39).
Furthermore, both ghrelin and its receptor are expressed
in human and rat pancreatic islets (on -, -, and ε -cells)
(16,18,20,40), and normal mouse pancreas contains a small
population of ghrelin producing ε -cells which appear to be
distinct from - and -cells (22,41). Ghrelin-immunoreac-
tive cells are abundant in human islets during develop-
ment, outnumbering those in the stomach, but few are
present in adults (20). It is interesting to note that mice
lacking the homeodomain protein Nkx2.2, which is essen-
tial for the differentiation of insulin-producing -cells,
have islets in which the -cells are almost completely
replaced by ε -cells (22). These ﬁndings raise the possibility
of a shared common progenitor for both - and ε -cells and
suggest a role of ghrelin in the pancreatic islet, perhaps as
a regulator of glucose homeostasis. Lastly, gut-brain
crosstalk has been well described, and it is possible that
ghrelin achieves its metabolic actions in the pancreas,
muscle, adipose tissue, and liver via central ghrelin and
insulin signaling (42–44).
As for possible indirect mechanisms of ghrelin action on
the islet, previous studies in animals and humans have
shown that both epinephrine and cortisol exhibit inhibi-
tory effects on insulin secretion (33–36). We have shown
here that cortisol levels were signiﬁcantly elevated when
higher doses of acyl ghrelin were given (0.9 and 1.5
nmol/kg/h). However, since steroid hormone action is
thought to be mediated primarily by changes in gene
transcription (45), it seems unlikely that the acute effect of
ghrelin on AIRg can be explained by glucocorticoid activ-
ity. In contrast to a previous observation (46), we did not
observe an increase in epinephrine levels with ghrelin
administration. This could be caused by the difference in
assay reproducibility (or perhaps sensitivity) or the
method of ghrelin administration. As expected, GH levels
were signiﬁcantly elevated during ghrelin infusion (Fig. 5).
Acutely, infusion of GH to levels within the physiologic
range (27  2 ng/ml) decrease insulin-mediated glucose
uptake in the periphery within 2 to 12 h (37). In this study,
the plasma insulin response to hyperglycemia was not
altered by GH, and other investigators have noted in-
creased plasma insulin concentration after 12-h infusion of
GH to healthy volunteers (38). Therefore, we do not think
the effects of ghrelin to reduce AIRg can be explained by
changes in plasma GH.
Theoretically, the decrease in insulin secretion with
ghrelin administration could be an adaptation to an in-
crease in peripheral insulin sensitivity. However, previous
studies in humans and animals seem to suggest that
ghrelin consistently reduces, rather than improves, periph-
eral insulin sensitivity (12,28,32,47). The length of the
IVGTT was limited by the total dose of ghrelin we could
administer to each individual based on FDA requirements.
For this reason, we do not have insulin sensitivity mea-
sures from IVGTT in this study. Overall, our data do not
support indirect actions of counter-regulatory hormones
or systemic insulin sensitivity to mediate the effects of
ghrelin on insulin secretion.
Although in this study the effects of ghrelin on -cell
function occurred at supraphysiologic concentrations, it is
important to consider that since ghrelin is produced in the
islet ε cells (20–21), intraislet ghrelin concentrations may
reach very high levels, raising the possibility that ghrelin
could act locally on  cells via paracrine mechanisms
(48–49), similarly to what has been demonstrated in adult
rat islets (16). It is generally accepted that the level of
hormone working in a paracrine/autocrine manner is
higher than that working in an endocrine manner. There-
fore, our observation of a suppressive effect of ghrelin on
insulin secretion while the circulating level is in the
supraphysiologic range does not exclude the possibility of
a physiologic function of this hormone. Further studies
will be necessary to delineate mechanisms by which
endogenous ghrelin may affect islet function. Based on our
results, endocrine, paracrine, and neural mechanisms are
all plausible possibilities.
The role of ghrelin on -cell function in humans has
not been well established. Glucagon secretion is en-
hanced by ghrelin in vitro (25), but the effect of ghrelin
on its release is less impressive in vivo, with levels
largely unchanged or mildly increased after ghrelin
administration (23,25,29,32). In our hands, no relevant
change in glucagon level was seen with pharmacologic
level ghrelin administration during fasting or IVGTT.
Future studies that employ measurement of dynamic
changes of glucagon level using more sensitive methods
should be done to conﬁrm this ﬁnding.
Conclusion. Our study demonstrates that exogenous
ghrelin markedly reduces the ﬁrst-phase insulin and C-
peptide responses to intravenous glucose in healthy hu-
mans. These ﬁndings raise the possibility that endogenous
ghrelin has a role in physiologic insulin secretion, and that
ghrelin antagonists could improve -cell function and
serve as a novel drug target for the treatment of type 2
diabetes.
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